glp-1 during pregnancy Preconception receptor agonist use may reduce risks GLP-1 Fertility: Why Weight Loss

Slows Gastric Emptying: By slowing the stomach emptying, GLP-1 helps you feel full longer after eating, reducing overall food intake

Your body requires steady semaglutide presence to maintain the neurological and metabolic adaptations that suppress hunger and improve glucose control

To view or add a comment, sign in In a sign of accelerating reshoring efforts, US-based contract drug manufacturers Cambrex and Wilmington PharmaTech (WPT) are making major investments to expand pharmaceutical chemical production capacity

Key Highlights Orforglipron (Eli Lilly) * 13.6% weight loss in Phase 2 * 2.1% HbA1c reduction * Highest efficacy among the three molecules in Phase 2 * Subsequently confirmed efficacy in Phase 3 with up to 14.7% weight loss * First and only FDA-approved oral small-molecule GLP-1 receptor agonist (Foundayo) Elecoglipron (AstraZeneca) * 11.8% weight loss * 1.9% HbA1c reduction * Strong Phase 2b results * Currently advancing into a global Phase 3 program Aleniglipron (Structure Therapeutics) * 12.1% weight loss * 1.5% HbA1c reduction * Encouraging efficacy with ongoing Phase 3 development Phase 2 Efficacy Comparison Weight Loss * Orforglipron: 13.6% * Aleniglipron: 12.1% * Elecoglipron: 11.8% HbA1c Reduction * Orforglipron: 2.1% * Elecoglipron: 1.9% * Aleniglipron: 1.5% As Structure Therapeutics expanded their testing into the ACCESS II trial and evaluated higher doses (specifically escalation protocols reaching 180 mg and 240 mg), the efficacy numbers jumped significantly

54: (Suppl 4): 9-18